Evaluating methylphenidate as a potential treatment for cocaine use disorder: a propensity score-matched study

Area of Science:

• Pharmacology
• Neuroscience
• Public Health

Background:

• Cocaine exerts psychoactive effects mainly through dopamine transporter (DAT) inhibition.
• Methylphenidate, also a DAT inhibitor, has shown potential in reducing cocaine use, but real-world evidence is scarce.
• Limited data exist on methylphenidate's effectiveness in treating cocaine use disorder in real-world clinical settings.

Purpose of the Study:

• To investigate the association between methylphenidate exposure and the likelihood of subsequent positive cocaine screens in US veterans.
• To compare the effects of methylphenidate versus no exposure and bupropion on cocaine use.
• To provide real-world data on methylphenidate's potential role in managing cocaine use disorder.

Main Methods:

• Retrospective cohort study utilizing Veterans Affairs Informatics and Computing Infrastructure (VINCI) data.
• Inclusion of 109,608 patients with a positive cocaine screen, comparing 503 methylphenidate-exposed patients to unexposed patients and bupropion users.
• Propensity score matching and logistic regression with generalized estimating equations to analyze one-year follow-up data for positive cocaine screens.

Main Results:

• Methylphenidate exposure was linked to significantly lower odds of a positive cocaine screen compared to no exposure (OR=0.71).
• Methylphenidate also showed reduced odds of positive cocaine screens compared to bupropion (OR=0.60).
• These findings were observed in a large, real-world cohort of US veterans.

Conclusions:

• Methylphenidate exposure is significantly associated with decreased cocaine detection in a large veteran population.
• The study supports methylphenidate as a potential pharmacologic treatment for cocaine use disorder.
• Methylphenidate demonstrated superior outcomes compared to no exposure or bupropion in this cohort.